FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W156717385> ?p ?o ?g. }

• W156717385 abstract "Refractory acute myeloid leukemia (R-AML), defined as primary resistance to induction chemotherapy, early relapse (within 6-12 months from remission), and second or subsequent relapse, is typically a multidrugresistant illness, for which effective treatment is presently lacking. We have treated R-AML patients with a combination of intermediatedose ara-C, carboplatin and either mitoxantrone or idarubicin in a cross-over design, obtaining an encouraging response rate (46%) in a small group of 13 R-AML patients who were given an amended, low-toxicity regimen [1]. Five more patients were treated with a similar carboplatin-containing schedule delivered in a sequential manner, but only one remission was achieved, to an overall response rate of 33% (6/18). This result prompted a further change in retreatment strategy. In R-AML, clinical multidrug resistance is often associated with functional overexpression of the MDR1 drug efflux machinery and/or other mechanisms such as LRP (lung-related protein) and MRP (multidrug resistance-associated protein) [2-11]. Theoretically, in view of the high incidence of MDR1 activation in R-AML and its adverse clinical significance, functional MDR1 inhibition with cyclosporin A (CsA), verapamil, tamoxifen, PSC 833, quinine [12-19] or the use of drugs scarcely (Idarubicin=IDR) or not (high-dose ara-C=HiDAC, carboplatin) MDR1-sensitive could underlie therapeutic improvement. In preclinical in vitrostudies on a MDR1+ human leukemic cell line [20,21], we found that both cellular uptake and pro-apoptotic effects of IDR used at therapeutic concentration (50-100 ng/ml, corresponding to the ranges of peak plasma level obtainable after rapid intravenous administration of IDR 10-12 mg/m2) were significantly increased by co-incubation with CsA 1500 ng/ml. Interestingly, CsA enhanced IDR-related cytotoxicity only in the early phase of IDR-blast cell interaction while, contrary to daunorubicin, 12-hour IDR retention by blast cells was not modified by CsA. The study conclusion was that both cellular uptake of and related biologic effects from IDR can be upregulated by CsA in MDR1+ cells but, partly because IDR is highly lypophilic and partly because it is less vulnerable to MDR1, this effect does not require a prolonged CsA exposure. On this basis we initiated a new clinical study, using CsA and aiming to determine the upper IDR concentration tolerated by patients with R-AML. This new sequential regimen included HiDAC 3 g/m2 every 12 hours for two consecutive days followed by IDR 12.5 mg/m2 as starting dose level (both drugs were given for two times on days 1-3 and 8-10) together with CsA 6 mg/kg over 1 hour and then 7.5 mg/kg over 11 hours according to the List schedule [22]. IDR was delivered 4 hours after starting CsA. The three-day sequence was repeated on days 8-10. Recombinanat human granulocyte colony-stimulating factor (G-CSF) was administered from day 11 until response evaluation. We report the therapeutic results obtained in the first 10 patients, who received IDR from 12.5 to 17.5 mg/m2/dose." @default.
• W156717385 created "2016-06-24" @default.
• W156717385 creator A5004450449 @default.
• W156717385 creator A5010698340 @default.
• W156717385 creator A5031853086 @default.
• W156717385 creator A5038898384 @default.
• W156717385 creator A5042134519 @default.
• W156717385 creator A5069072959 @default.
• W156717385 date "2001-01-01" @default.
• W156717385 modified "2023-09-27" @default.
• W156717385 title "Split-Course High-Dose ARA-C Plus Idarubicin and Multidrug Blockade by short Cyclosporin-A Infusion for Refractory Acute Myeloid Leukemia" @default.
• W156717385 cites W153446213 @default.
• W156717385 cites W1537239037 @default.
• W156717385 cites W1591450638 @default.
• W156717385 cites W1723032639 @default.
• W156717385 cites W1949997781 @default.
• W156717385 cites W1950536611 @default.
• W156717385 cites W1996264890 @default.
• W156717385 cites W1997498784 @default.
• W156717385 cites W2003448477 @default.
• W156717385 cites W2085436951 @default.
• W156717385 cites W2091637935 @default.
• W156717385 cites W2105451308 @default.
• W156717385 cites W2198835790 @default.
• W156717385 cites W2228456847 @default.
• W156717385 cites W2288226674 @default.
• W156717385 cites W2322652491 @default.
• W156717385 cites W2393023456 @default.
• W156717385 cites W2416083307 @default.
• W156717385 cites W2431955049 @default.
• W156717385 cites W333222395 @default.
• W156717385 cites W61975600 @default.
• W156717385 doi "https://doi.org/10.1007/978-3-642-18156-6_71" @default.
• W156717385 hasPublicationYear "2001" @default.
• W156717385 type Work @default.
• W156717385 sameAs 156717385 @default.
• W156717385 citedByCount "0" @default.
• W156717385 crossrefType "book-chapter" @default.
• W156717385 hasAuthorship W156717385A5004450449 @default.
• W156717385 hasAuthorship W156717385A5010698340 @default.
• W156717385 hasAuthorship W156717385A5031853086 @default.
• W156717385 hasAuthorship W156717385A5038898384 @default.
• W156717385 hasAuthorship W156717385A5042134519 @default.
• W156717385 hasAuthorship W156717385A5069072959 @default.
• W156717385 hasConcept C114851261 @default.
• W156717385 hasConcept C126322002 @default.
• W156717385 hasConcept C133936738 @default.
• W156717385 hasConcept C143998085 @default.
• W156717385 hasConcept C2776694085 @default.
• W156717385 hasConcept C2778041864 @default.
• W156717385 hasConcept C2778239845 @default.
• W156717385 hasConcept C2778729363 @default.
• W156717385 hasConcept C2779117419 @default.
• W156717385 hasConcept C2780923524 @default.
• W156717385 hasConcept C2781451048 @default.
• W156717385 hasConcept C71924100 @default.
• W156717385 hasConcept C86803240 @default.
• W156717385 hasConcept C89423630 @default.
• W156717385 hasConcept C98274493 @default.
• W156717385 hasConceptScore W156717385C114851261 @default.
• W156717385 hasConceptScore W156717385C126322002 @default.
• W156717385 hasConceptScore W156717385C133936738 @default.
• W156717385 hasConceptScore W156717385C143998085 @default.
• W156717385 hasConceptScore W156717385C2776694085 @default.
• W156717385 hasConceptScore W156717385C2778041864 @default.
• W156717385 hasConceptScore W156717385C2778239845 @default.
• W156717385 hasConceptScore W156717385C2778729363 @default.
• W156717385 hasConceptScore W156717385C2779117419 @default.
• W156717385 hasConceptScore W156717385C2780923524 @default.
• W156717385 hasConceptScore W156717385C2781451048 @default.
• W156717385 hasConceptScore W156717385C71924100 @default.
• W156717385 hasConceptScore W156717385C86803240 @default.
• W156717385 hasConceptScore W156717385C89423630 @default.
• W156717385 hasConceptScore W156717385C98274493 @default.
• W156717385 hasLocation W1567173851 @default.
• W156717385 hasOpenAccess W156717385 @default.
• W156717385 hasPrimaryLocation W1567173851 @default.
• W156717385 hasRelatedWork W132959109 @default.
• W156717385 hasRelatedWork W1602123006 @default.
• W156717385 hasRelatedWork W1975309857 @default.
• W156717385 hasRelatedWork W2032585021 @default.
• W156717385 hasRelatedWork W2057484677 @default.
• W156717385 hasRelatedWork W2088419541 @default.
• W156717385 hasRelatedWork W2143244096 @default.
• W156717385 hasRelatedWork W2331244012 @default.
• W156717385 hasRelatedWork W2387126591 @default.
• W156717385 hasRelatedWork W2399601929 @default.
• W156717385 hasRelatedWork W2467225938 @default.
• W156717385 hasRelatedWork W2531339322 @default.
• W156717385 hasRelatedWork W2535637335 @default.
• W156717385 hasRelatedWork W2550175900 @default.
• W156717385 hasRelatedWork W2551213669 @default.
• W156717385 hasRelatedWork W2553566409 @default.
• W156717385 hasRelatedWork W2576736597 @default.
• W156717385 hasRelatedWork W2587586062 @default.
• W156717385 hasRelatedWork W2781538167 @default.
• W156717385 hasRelatedWork W2980047921 @default.
• W156717385 isParatext "false" @default.
• W156717385 isRetracted "false" @default.
• W156717385 magId "156717385" @default.

• next